Switzerland· 62997001
Etoposid Fresenius
A etoposide product, registered in Switzerland by Fresenius Kabi (Schweiz) AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Etoposide is registered in 17 of 19 countries.
Countries holding a registration under ATC L01CB01 (etoposide), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 10 of them publish a price we can compare per daily dose
Etoposide · ATC L01CB01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of etoposide costs, country by country.
Normalised to the WHO defined daily dose (50 mg), the median price runs from $9.95 in France to $18.65 in Switzerland — a ×1.9 gap.
- Switzerland: $18.65 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Etoposide · price per daily dose (50 mg)
USD · FX 28 Sept 2026
- CH Switzerland$18.65
- FR France$9.95
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Manufacturer
- Fresenius Kabi (Schweiz) AG
- Country
- Switzerland (CH)
- ATC code
- L01CB01
- ATC class
- Etoposide
- Defined daily dose
- 50 mg, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- gtin7680629970019Durchstf 5 mlCHF 38.85
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
576 interactions on record for etoposide.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Etoposide · interactions on record
576 records
- 30 severe
- 290 moderate
- 21 minor
- 235 info
Most severe, free to view
- CladribineL01BB04severe
- AprepitantA04AD12moderate
- RolapitantA04AD14moderate
- EliglustatA16AX10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01CB01
Etoposide, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ff0704ec-687d-45ce-8560-88c257681f45 GET /v1/drugs/ff0704ec-687d-45ce-8560-88c257681f45?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "etoposidum 100 mg",
"valid_from": "2014-06-01",
"limitations": null,
"galenic_form": "Inf Konz 100 mg/5ml",
"therapeutic_area": null,
"sl_inclusion_date": "2014-06-01",
"self_retention_pct": 10
}See everything about etoposide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.